


PRODUCT INFORMATION



NVP-ACC789

Item No. 23458

CAS Registry No.: 300842-64-2
Formal Name: N-(3-bromo-4-methylphenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine
MF: C₂₁H₁₇BrN₄
FW: 405.3
Purity: ≥98%
UV/Vis.: λ_{max}: 215, 337 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

NVP-ACC789 is supplied as a crystalline solid. A stock solution may be made by dissolving the NVP-ACC789 in the solvent of choice, which should be purged with an inert gas. NVP-ACC789 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of NVP-ACC789 in these solvents is approximately 0.2, 1, and 0.5 mg/ml, respectively.

NVP-ACC789 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, NVP-ACC789 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. NVP-ACC789 has a solubility of approximately 0.09 mg/ml in a 1:10 solution of DMF:PBS (pH 7) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

NVP-ACC789 is an inhibitor of VEGF receptor tyrosine kinases (VEGFRs; IC₅₀s = 0.38, 0.02, 0.18, and 0.23 μM for human VEGFR1, 2, 3, and mouse Vegfr2, respectively).¹ It is selective for VEGFRs over FGFRs and PDGFRα (IC₅₀s = >10 μM) but has activity at PDGFRβ (IC₅₀ = 1.4 μM) in an enzyme assay. NVP-ACC789 inhibits VEGF-induced VEGFR2 autophosphorylation (IC₅₀ = 11.5 nM in CHO cells transfected with the human receptor). It also inhibits VEGF- and bFGF-induced angiogenesis and cell migration of BAE and BME cells. *In vivo*, NVP-ACC789 blocks bFGF- and VEGF-induced angiogenesis (ED₅₀s = 9 and 26 mg/kg, respectively) in a mouse model of growth factor-induced angiogenesis.

Reference

1. Tille, J.C., Wood, J., Mandriota, S.J., *et al.* Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. *J. Pharmacol. Exp. Ther.* **299**(3), 1073-1085 (2001).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/18/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM